Neuroprotective Effect of Chebulagic Acid via Autophagy Induction in SH-SY5Y Cells

Hee Ju Kim¹, Joonki Kim¹, Ki Sung Kang¹, Keun Taik Lee² and Hyun Ok Yang¹*  
¹Natural Medicine Center, Korea Institute of Science and Technology, Gangneung 210-340,  
²Gangneung-Wonju National University, Gangneung 210-702, Republic of Korea

Abstract
Autophagy is a series of catabolic process mediating the bulk degradation of intracellular proteins and organelles through formation of a double-membrane vesicle, known as an autophagosome, and fusing with lysosome. Autophagy plays an important role of death-survival decisions in neuronal cells, which may influence to several neurodegenerative disorders including Parkinson’s disease. Chebulagic acid, the major constituent of Terminalia chebula and Phyllanthus emblica, is a benzopyran tannin compound with various kinds of beneficial effects. This study was performed to investigate the autophagy enhancing effect of chebulagic acid on human neuroblastoma SH-SY5Y cell lines. We determined the effect of chebulagic acid on expression levels of autophagosome marker proteins such as, DOR/TP53INP2, Golgi-associated ATPase Enhancer of 16 kDa (GATE 16) and Light chain 3 II (LC3 II), as well as those of its upstream pathway proteins, AMP-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR) and Beclin-1. All of those proteins were modulated by chebulagic acid treatment in a way of enhancing the autophagy. Additionally in our study, chebulagic acid also showed a protective effect against 1-methyl-4-phenylpyridinium (MPP⁺) - induced cytotoxicity which mimics the pathological symptom of Parkinson’s disease. This effect seems partially mediated by enhanced autophagy which increased the degradation of aggregated or misfolded proteins from cells. This study suggests that chebulagic acid is an attractive candidate as an autophagy-enhancing agent and therefore, it may provide a promising strategy to prevent or cure the diseases caused by accumulation of abnormal proteins including Parkinson’s disease.

Key Words: Parkinson’s disease, Autophagy, Chebulagic acid, 1-Methyl-4-phenylpyridinium (MPP⁺)
astrocytes, is the proximal neurotoxin destroying the nigrostriatal pathway in animals. Therefore, MPP⁺ has been widely used in in vitro and in vivo models of PD (Dauer and Przedborski, 2003; Bollimuntha et al., 2005; Choi et al., 2005).

Chebulagic acid (CA), the major constituent of Terminalia chebula and Phyllanthus emblica, is a benzopyran tannin compound with various kinds of medicinal potentials including anti-oxidative, anti-pyretic, anti-atherogenic, cardioprotective, hepatoprotective, nephroprotective, adaptogenic, anti-anemia and neuroprotective activities (Baliga and Dsouza, 2011; Park et al., 2011; Chang and Lin, 2012). However, effect of CA on autophagy is currently not reported. In this study, we used CA as an autophagy inducer to find out its neuroprotective mechanism via autophagy. Using this approach, our primary aim is to evaluate the therapeutic potential of CA for neurodegenerative diseases, especially in PD.

**MATERIALS AND METHODS**

**Cell culture and chemicals**

The human neuroblastoma cell line SH-SY5Y was from the American Type Culture Collection (Manassas, VA, USA). Cells were grown in Dulbecco's modified Eagle medium Ham's F12 (1:1 mixture) (Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Grand Island, NY, USA), 100 units/ml of penicillin, and 100 mg/ml of streptomycin (Grand Island, NY, USA) in a 5% CO₂ incubator at 37°C. CA was purchased from the Chromadex (Irvine, CA, USA). CA was dissolved in culture medium at a concentration of 5 mM for a stock solution. For treatment of cells, CA was diluted in culture medium to the appropriate concentration. 3-methyladenine (3MA) and MPP⁺ were obtained from Sigma (St. Louis, MO, USA).

**MTT assay**

The cell viability was measured by a quantitative colorimetric assay with MTT. The MTT assay provided a sensitive measurement of the metabolic status of the cells, particularly, the status of the mitochondria, which can reflect early redox changes. Briefly, exponentially growing cells were seeded in a 96-well plate at a density of 5×10⁴ cells/well. The next day, cells were treated with various concentrations of CA in triplicate. After incubation for 24 h, 10 μl of the MTT assay kit reagent was added to each well, and the cells were incubated for an additional hour. Another set of MTT assay was done with cells treated with MPP⁺. SH-SYSY cells were plated at a density of 5×10⁴ cells/well in 100 μl medium in 96-well plates and incubated for 24 h. The cells were then pre-treated with CA for 2 h. After the pre-treatment period, 600 μM MPP⁺ was added to the culture medium and incubated for 48 h. The control cells were not treated with CA or MPP⁺. The absorbance for each reaction product was measured with a microplate reader at a wavelength of 450 nm. The results are expressed as the percentage of MTT reduction, with the assumption that the ab-
sorbance of the control cells is 100%.

**Immunoblot analysis**

Whole-cell lysates were prepared by incubating cells in RIPA buffer (Beverly, MA, USA) supplemented with protease inhibitor cocktail (Roche, Mannheim, Germany) according to the manufacturer’s instructions. Briefly, cells were harvested and collected by centrifugation at 13,200 rpm for 5 min and washed in Dulbecco’s Phosphate-Buffered Saline (DPBS) (pH 7.2). The pellets were solubilized in the same volume of mitochondrial lysis buffer for 5 min and then centrifuged at 13,200 rpm for 20 min at 4°C. Equal amounts of lysate protein were loaded and separated on a 15% SDS-PAGE gel. Proteins were electrophoretically transferred to a PVDF membrane, and the membrane was blocked in 5% skim milk in tris-buffered saline containing 0.1% Tween-20 for 1 h. Then, the membranes were incubated in the presence of following primary antibodies (LC3, beclin-1, mTOR, AMPK, GAPDH from cell signaling (Beverly, MA, USA); GATE16, TP53INP2/DOR from Epitomics (Burlingame, CA, USA)) at 4°C overnight. The membranes were then washed three times with TBS Tween 20 and probed with the corresponding secondary antibodies conjugated with HRP at room temperature for 1 h. Detection was carried out using an enhanced ECL Advance Western Blotting Detection Reagents (GE Healthcare, Buckinghamshire, UK) followed by LAS-4000 film (Fuji film, Tokyo, Japan).

**Immunofluorescence analysis**

To detect the expression of LC3, cells were seeded onto sterile coverslips that were placed in 12-well plates. The next day, the cells were treated with CA. At 24 h post-treatment, the cells were fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.2% Triton X-100 for 30 min, blocked with 2% Bovine serum albumin (BSA) in Dulbecco’s Phosphate buffered saline (DPBS) for 1 h, and incubated with the LC3B primary antibody at room temperature (RT) for 1 h and with the Alexa fluor 488 secondary antibody (Invitrogen) at RT for 1 h in the dark. This was followed by incubation with 1 mg/ml of 40,60-diamidino-2-phenylindole (DAPI) at RT for 20 min in the dark. Slides were then prepared with one drop of Pro-Long Gold Antifade Reagent (Invitrogen), and the coverslips were sealed onto the slides with clear nail lacquer. The images were obtained using a Leica TCS SP5 confocal microscope (Leica, Mannheim, Germany) and the pictures were analyzed by Image-Pro Plus 6.0 (Bethesda, MD, USA).

**Statistical analysis**

Statistical data are expressed as mean ± SD and student’s t-test was used to determine statistical significance. Values of p<0.05 were considered to be statistically significant.

**RESULTS**

**CA induced autophagy in SH-SY5Y cells without cytotoxicity**

To evaluate the potential cytotoxicity of CA, we first examined the effect of CA on cell survival in SH-SY5Y cells. SH-SY5Y cells were treated with CA at various concentrations (1.56, 3.13, 6.25, 12.5 and 25 μM) for 24 h. Cell viability was measured by using the MTT assay kit. MTT assay result indicated that CA treatment has no cytotoxicity on SH-SY5Y cell compared to vehicle-treated control group (Fig. 1A). To determine the induction of autophagy by CA in SH-SY5Y cells, the cells were treated with various concentrations of CA at 1.56 to 25 μM for 24 h. Immunoblot assay revealed that the ratio of LC3 II/I was significantly increased in a dose-dependent manner with CA treatment as compared with control. Also the expression of other autophagosome markers such as,
TP53INP2/DOR and GATE16 showed tendency to increase with CA treatment (Fig. 1B, C).

CA regulated the expression of autophagy modulating proteins in SH-SY5Y cells

To determine the mechanism of CA on autophagy induction in SH-SY5Y cells, the cells were treated with CA at the concentration of 1.56, 3.13, 6.25, 12.5 and 25 μM. As shown in Fig. 2, the expression levels of p-AMPK and Beclin-1 were significantly upregulated, whereas mTOR was downregulated by CA treatment.

CA-regulated autophagy expressions were inhibited by 3MA in SH-SY5Y cells

As shown in Fig. 3, the ratio of LC3 II/I and expression of Beclin-1 were increased by the treatment of rapamycin (10 μM, positive control) and CA (25 μM), while mTOR expression level showed tendency to decrease. However, increased ratio of LC3 II/I proteins by CA was inhibited with 3MA treatment (Per and Paul, 1982; Bae et al., 2011), a specific inhibitor of beclin-1 in early stage of autophagosome formation, whereas mTOR expression level showed tendency to increase.

To visualize such effect of CA in SH-SY5Y cells with or without the treatment of 3MA, confocal imaging analysis was conducted. As shown in Fig. 4, cytosolic LC3 fluorescent puncta was significantly increased by rapamycin and CA treatments. However, 3MA treatment significantly inhibited such expression of LC3 puncta.

CA showed protective effect against MPP⁺-induced cytotoxicity in SH-SY5Y cells

SH-SY5Y cells were treated with CA at the concentrations of 1.56, 3.13, 6.25, 12.5 and 25 μM for 2 h. Then MPP⁺ (600 μM) was added and cells were incubated for another 48 h. As shown in Fig. 5, MPP⁺ caused a significant cytotoxicity on SH-SY5Y cells. However, this cytotoxicity was attenuated by CA treatment in a dose-dependent manner.

DISCUSSION

Basal expression of autophagy acts as one of the cytoprotective mechanisms and participates in maintaining homeostasis (Hara et al., 2006; Dadakhujayev et al., 2010). Also in diseased conditions, autophagy enhancement is known to play a role as protective mechanism. The results are consistent with previous studies supporting the putative neuroprotective effects of rapamycin, an autophagy enhancing agent, in various kinds of neurodegenerative disorders including PD (Ravikumar et al., 2006; Pan et al., 2008a; Pan et al., 2009; Underwood et al., 2010). Autophagy is the bulk degradation of proteins and organelles which is, essential for cellular maintenance and cell survival. Recently, LC3, DOR/TP53INP2 and GATE16 have been reported as new regulators involved in mammalian autophagy (Nowak et al., 2009; Spowart and Lum, 2010). LC3, GATE 16 and DOR co-localize during autophagosome formation and DOR/TP53INP2 has a short life cycle and degraded during fusion process of autophagosome and lysosome (Kabeya et al., 2004; Tanida et al., 2004; Nowak and Iovanna, 2009; Mauvezin et al., 2010; Weidberg et al., 2010). In this study, we demonstrated CA can induce LC3, GATE 16 and DOR/TP53INP2 protein expressions without any cytotoxicity (Fig. 1). These results indicate that CA can effectively increase the formation of autophagosomes which can dispose aggregated or misfolded proteins by fusing with lysosomes.
To elucidate the specific action mechanism of CA on enhancing the autophagy, we investigated some kinds of the most important proteins related with autophagy. Beclin-1 was originally isolated from a yeast two-hybrid screen for Bcl-2 interacting proteins and has been shown to interact with anti-apoptosis protein such as Bcl-2 and Bcl-xL, and is also a principal regulator in autophagosome formation which initiates autophagy through class III PI3K pathway (Liu et al., 2007; Ko et al., 2011). mTOR, a mammalian target of rapamycin, acts as an inhibitor protein of autophagy mechanism (Gurusamy et al., 2010; Han et al., 2012). In this study, CA significantly induced Beclin-1 protein expression in dose dependent manner. Also, CA significantly attenuated protein expression of mTOR in dose dependent manner. Next, our study expanded to the upstream regulator of mTOR, AMPK protein. AMPK, AMP activated protein kinase, is a key energy sensor and can regulate metabolism (Williams et al., 2009; Wu et al., 2011). AMPK demonstrated conflicting roles for mTOR in autophagy. Several studies indicated that AMPK is an inducer of autophagy and many studies focus on it as a pharmacological agent (Melendez et al., 2003; Patschan et al., 2008; Williams et al., 2009; Wu et al., 2011). Our results showed that CA can increase the phosphorylated form of AMPK in a dose dependent manner. Taken together, CA revealed that it enhances autophagy through modulation of various kinds of proteins not only in lower stream of autophagy mechanism but also the proteins working in upper stream of the mechanism, too.

Furthermore, we investigated whether enhancement of autophagy by CA will be inhibited by 3MA treatment, the most commonly used specific inhibitor of autophagic removal. 3MA has an inhibitory effect on autophagy in the early stage of autophagosome formation and is thought to induce inhibition of class III PI3K (Bae et al., 2011). In this study, LC3II and beclin-1 were upregulated in the rapamycin and CA treated cells, and the protein expression levels of LC3 and beclin-1 were suppressed by the co-treatment of CA and 3MA. Recent reports have shown 3MA inhibits class III PI3K-mediated mTOR suppression, resulting in autophagy induction (Bae et al., 2011; Ko et al., 2011; Bao et al., 2012). In this study, mTOR was suppressed in the CA and rapamycin treated cells, and the protein expression level of mTOR was increased by the co-treatment of CA and 3MA. Therefore, CA acts similarly as rapamycin, a well established autophagy inducer via suppression of mTOR function (Fig. 3, 4).

**Fig. 4.** CA-induced LC3 expression in autophagosomes. SH-SY5Y cells were treated with 25 μM of CA, 10 μM of rapamycin and 5 mM of 3MA for 24 h and then, were labeled with 40, 6-diamidino-2-phenylindole (DAPI, blue), and Alexa 488 secondary antibody against LC3 (green). LC3 fluorescent puncta were observed in cells by using the confocal microscope.
Currently in clinics, Levo-dopa is used for PD patients to increase dopamine concentration in the brain and other neurodegenerative diseases (Chen et al., 2003; Bollimuntha et al., 2005; Bae et al., 2011). But, several studies showed that Levo-dopa has side effects such as wearing-off and dyskinesia (Chen et al., 2003; Choi et al., 2005; Bae et al., 2011).

Recently, the PD etiology and mechanisms related to dopaminergic neuronal death became focused for prevention and alleviating the progress of PD (Chen et al., 2003; Bollimuntha et al., 2005). Research on PD models were created by using toxic materials such as 6-OHDA and MPTP which were known to selectively destroy dopaminergic neurons. MPP⁺, the active neurotoxic metabolite converted from MPTP by monoamine oxidase-B in astrocytes, is the proximal neurotoxin destroying neurotoxic materials such as 6-OHDA and MPTP which were known to selectively destroy dopaminergic neurons.

CA showed significant neuroprotective effect against MPP⁺-induced cellular damages and it may possess protective function against PD-related neuronal damages which needs to be elucidated in future studies.

ACKNOWLEDGMENTS

This work was supported by the institutional program of the Korea Institute of Science and Technology (Grant No. 2Z04210), The Business Promotion of the “Baekduadaegan Greenmine” Resource program (Grant No. R0000487), and Bio-Synergy Research Project (NRF-2012M3A9C4048793) of the Ministry of Science, ICT and Future Planning through the National Research Foundation, Republic of Korea.

REFERENCES


Baliga, M. S. and Dsouza, J. J. (2011) Amla(Emblica of Greenmine” Resource program (Grant No. R0000487), and Bio-Synergy Research Project (NRF-2012M3A9C4048793) of the Ministry of Science, ICT and Future Planning through the National Research Foundation, Republic of Korea.


